Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873102 | 0.86 | BRD4 (0.47) | BRD4KMT2ARAB9A | |
| SCHEMBL12667390 | 0.85 | BRD4 (0.64) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL3133394 | 0.85 | BRD4 (0.64) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL8292848 | 0.84 | L3MBTL1 (0.51) | L3MBTL1KMT2AMEN1CYP2C19RAB9A | |
| SCHEMBL9368854 | 0.81 | BRD4 (0.62) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL23177805 | 0.80 | BRD4 (0.60) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL12668081 | 0.80 | BRD4 (0.60) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL121038 | 0.80 | BRD4 (0.60) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL15042008 | 0.80 | BRD4 (0.60) | L3MBTL1BRD4KMT2AMEN1CYP2C19 | |
| SCHEMBL15042026 | 0.80 | BRD4 (0.60) | L3MBTL1BRD4KMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1863770-B | Cyclic amine BASE-1 inhibitors having a heterocyclic substituent | SCHERING CORP | 2011-05-25 | — | — | CN | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| CN-1863770-A | Cyclic amine BASE-1 inhibitors having a heterocyclic substituent | SCHERING CORP AND PHARMACOPEIA (US) | 2006-11-15 | — | — | CN | disclosed |
| EP-1660447-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | BACE1, BACE2, PSEN1 | L3MBTL1 2191/4885BRD4 278/4885KMT2A 3816/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | L3MBTL1 2191/4885BRD4 278/4885KMT2A 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.